Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
US immuno-dermatology specialist biotech Dermavant Sciences, a subsidiary of Roivant Sciences, has appointed John Darden as vice president of marketing. 6 October 2023
A privately-held drug discovery company based in San Diego, USA, has raised $100 million in a series B financing co-led by Ascenta Capital and Abingworth. 5 October 2023
Shares of US and UK-based gene therapy company Orchard Therapeutics almost doubled to $16.03 in pre-market activity today, on the news that it has received a takeover offer from mid-size Japanese drugmaker Kyowa Kirin. 5 October 2023
Shares of Melbourne, Australia-based Dimerix shot up 154% to A$0.16 on the news of a licensing deal with privately-held UK-based drugmaker Advanz Pharma. 5 October 2023
At an investor day in New York, Californian biotech Ionis Pharmaceuticals outlined key clinical and commercial updates related to its progress developing RNA-based medicines. 5 October 2023
California-based Vistagen Therapeutics, a company aiming to transform the treatment landscape for anxiety, depression, and other central nervous system (CNS) disorders, has raised $100 million through an underwritten offering of its common stock. 4 October 2023
US clinical-stage immuno-oncology company ALX Oncology Holdings saw its shares rocket 56% to $7.51 yesterday, as it announced positive clinical results for its lead asset after a previous disappointment. 4 October 2023
Fred Hassan, an industry veteran behind some of the biggest pharma M&A deals in the past two decades, has been named as chairman of Saghmos Therapeutics. 4 October 2023
UK respiratory disease focussed biotech Synairgen today announced the appointment of Dr Marcin Mankowski as chief medical officer (CMO), effective immediately. 3 October 2023
Despite positive top-line data, Syndax Pharmaceuticals stock has fallen more than a tenth, following an interim analysis from the AUGMENT-101 trial. 3 October 2023
Today, Boston, USA-based Clade Therapeutics announced the acquisition of Gadeta, a Netherlands-based cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. 2 October 2023
Madrigal Pharmaceuticals, a US biopharma pursuing new therapeutics for non-alcoholic steatohepatitis (NASH), has announced the pricing of its underwritten public offering. 2 October 2023
A Chinese contract development and manufacturing organization (CDMO), Chime Biologics, has announced a strategic cooperation with South Korea’s Kings Pharm. 29 September 2023
Information from research group GlobalData suggests there is a pressing need for innovation and collaboration in China to address an unmet medical need in Fabry disease. 29 September 2023
After several delays, the US Food and Drug Administration (FDA) has finally approved Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for the treatment of late onset Pompe disease/LOPD. 29 September 2023